IDYA$33.91
$33.5
Chart
Performance
Key Stats
AI IDYA Summary
Powered by LiveAIAI Scoreboard
Powered by LiveAIOverall Analysis
HoldIDEAYA Biosciences, Inc. shows strong potential in precision medicine, with a promising pipeline and supportive strategic alliances. However, current financial performance indicates significant losses and high cash burn, while technical indicators are mixed. The company is a speculative play with high growth potential, but also carries substantial risk.
Thematic
IDEAYA Biosciences is positioned within the high-growth precision medicine and oncology sector, benefiting from advancements in genetic sequencing and targeted therapies. Its focus on molecular diagnostics aligns with current trends in personalized healthcare.
Fundamental
IDEAYA Biosciences shows a strong balance sheet with substantial cash reserves, but its current financial performance is characterized by significant operating losses and negative earnings, reflecting its development-stage status. Revenue is minimal, and profitability metrics are not yet applicable.
Technical
The stock has shown some positive momentum in the short term, trading above key moving averages. However, oscillators are mixed, suggesting a consolidation or potential minor pullback before further significant moves.
| Factor | Score |
|---|---|
| Precision Medicine Adoption | 85 |
| Oncology Market Growth | 80 |
| Biotech Innovation | 70 |
| Strategic Alliances | 75 |
| Regulatory Landscape | 65 |
| Factor | Score |
|---|---|
| Valuation | 40 |
| Profitability | 10 |
| Growth | 20 |
| Balance Sheet Health | 70 |
| Cash Flow | 20 |
| Factor | Score |
|---|---|
| Trend Analysis | 75 |
| Momentum | 60 |
| Volume Confirmation | 65 |
| Support & Resistance | 65 |
AI Investing Checklist
Powered by LiveAIBullish Points (6)
Bullish Momentum Indicators
On the 1m, 5m, 15m, 30m, 1h, 2h, 4h, and 1d timeframes, multiple moving averages (Exponential and Simple) are showing a 'Buy' signal, indicating positive short-to-medium term momentum.
Strong Cash Position
The company has a significant cash and cash equivalents balance of $84.38M as of Q4 2024, providing ample liquidity.
Bearish Points (8)
Significant Net Loss
The company reported a substantial net loss of -$274.48M for 2024Q4, with a very negative net margin of -3921.1%, indicating severe profitability challenges.
Consistent Negative EPS
Earnings Per Share (EPS) has been consistently negative, with a reported EPS of -0.82 for 2025Q2, significantly missing the estimate of -0.66.
Calendar
August 2025
5
Next Earnings Date
H: $-0.67
A: $-0.81
L: $-0.90
H: 8.30M
A: 3.48M
0Profile
IDEAYA Biosciences, Inc., a precision medicine oncology company, discovers and develops targeted therapeutics for patient populations selected using molecular diagnostics in the United States. The company's products in development include IDE196, a protein kinase C inhibitor that is in Phase 2/3 clinical trials for genetically defined cancers having GNAQ or GNA11 gene mutations; IDE397, a methionine adenosyltransferase 2a inhibitor that is in Phase 2 clinical trials for patients with solid tumors having methylthioadenosine phosphorylase gene deletions, such as non-small cell lung (SCLC) and MTAP-deletion urothelial cancer; IDE849, a DLL3 antibody drug conjugate inhibitor that is in Phase 1 clinical trial for the treatment of SCLC and neuroendocrine tumors; IDE275, a Werner Helicase inhibitor that is in Phase 1 clinical trial for patients having tumors with high microsatellite instability; IDE161, a poly ADP-ribose glycohydrolase inhibitor that is in Phase 1/2 clinical trial to treat tumors with homologous recombination deficiency (HRD), and other genetic or molecular signatures; IDE705 (GSK101), a Poly Theta Helicase inhibitor that is in Phase 1 clinical trial for the treatment of tumors with BRCA or other mutations associated with HRD. It also develops preclinical programs, including IDE892, a MTA-cooperative PRMT5 inhibitor; IDE034, a B7H3/PTK7 topo-I-payload bispecific BsADC; and IDE251, a KAT6/7 inhibitor. In addition, the company offers preclinical research programs focused on pharmacological inhibition; DECIPHER dual CRISPR library for synthetic lethality target and biomarker discovery; and INQUIRE chemical library and HARMONY machine-learning engines to enhance its drug discovery platform. The company has strategic alliances with GlaxoSmithKline, Pfizer Inc., Gilead Sciences, Inc., Merck, Biocytogen, Cancer Research UK, and the University of Manchester. IDEAYA Biosciences, Inc. was incorporated in 2015 and is headquartered in South San Francisco, California.
Seasonals
Price Target
51.08 USD
The 39 analysts offering 1 year price forecasts for IDYA have a max estimate of 66.00 and a min estimate of 27.00.
Debt Level and Coverage
Financial Position Analysis
Ownership
Capital Structure
Valuation - Summary
Valuation - Ratios
Revenue to Profit Conversion
Balance Sheet
Income Statement
Cash Flow
Related Companies
Powered by LiveAIWeight: 100
Direct strategic partner with Ideaya Biosciences on multiple oncology programs (e.g., AMG 919/IDE397, AMG 193/IDE705) targeting synthetic lethality pathways.
Weight: 95
A direct competitor and peer in precision oncology, highly focused on discovering and developing synthetic lethality and DNA damage response (DDR) targeting therapeutics.
Weight: 90
A leading pharmaceutical company with a strong oncology pipeline, particularly in targeted therapies and DNA Damage Response (DDR) with drugs like Lynparza (PARP inhibitor), making them highly relevant to Ideaya's focus.
Weight: 85
A major pharmaceutical company with a significant oncology portfolio, actively investing in and acquiring precision oncology assets, demonstrating interest in targeted cancer therapies.